Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper
Multiple myeloma is a bone marrow‐based plasma cell tumour that develops from asymptomatic pre‐cursor conditions smouldering myeloma and monoclonal gammopathy of uncertain significance and all are characterised by the presence of a monoclonal protein in the blood. Diagnosis and distinction between t...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2024-04, Vol.204 (4), p.1193-1206 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1206 |
|---|---|
| container_issue | 4 |
| container_start_page | 1193 |
| container_title | British journal of haematology |
| container_volume | 204 |
| creator | Hughes, Daniel Yong, Kwee Ramasamy, Karthik Stern, Simon Boyle, Eileen Ashcroft, John Basheer, Faisal Rabin, Neil Pratt, Guy |
| description | Multiple myeloma is a bone marrow‐based plasma cell tumour that develops from asymptomatic pre‐cursor conditions smouldering myeloma and monoclonal gammopathy of uncertain significance and all are characterised by the presence of a monoclonal protein in the blood. Diagnosis and distinction between these conditions is based on blood tests, the bone marrow biopsy and cross sectional imaging. There are various risk stratification models that group patients with smouldering myeloma into risk groups based on risk of progression to symptomatic disease. Management is mainly observational for patients with smouldering myeloma although clinical trials for high‐risk disease may be available. Restaging is required if evidence for progression. |
| doi_str_mv | 10.1111/bjh.19333 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2956680367</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2956680367</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3883-32980f1b19ca82cc01dd6bb8946373ac4d6d77133ed9cda704135340044279fd3</originalsourceid><addsrcrecordid>eNp10MFO3DAUhWGrKioD7aIvUFnqBhYB39wkdrobKDAgpCK1XVuO7QwexfFgJ6ry9gQGWCDVG28-_bo6hHwFdgLzO2029ydQI-IHsgCsyiyHAj6SBWOMZ8AKsU8OUtowBshK-ET2UWCNHMSCtD-dWvchuURVb6hXvVpbb_uBhpYmH8bO2Oj6NfWT7YJXP-iSnkU3uHRPfwft7DDRNkS6UtarIXRhPdGrEAy9i0oPTlt6p7Y2fiZ7reqS_fLyH5K_lxd_zlfZ7a-r6_PlbaZRCMwwrwVroYFaK5FrzcCYqmlEXVTIUenCVIZzQLSm1kZxVgCWWDBWFDmvW4OH5GjX3cbwMNo0SO-Stl2nehvGJPO6rCrBsOIz_f6ObsIY-_k6iQxLyMucP6njndIxpBRtK7fReRUnCUw-jS_n8eXz-LP99lIcG2_Nm3xdewanO_DPdXb6f0me3ax2yUcru4yC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3035125277</pqid></control><display><type>article</type><title>Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Hughes, Daniel ; Yong, Kwee ; Ramasamy, Karthik ; Stern, Simon ; Boyle, Eileen ; Ashcroft, John ; Basheer, Faisal ; Rabin, Neil ; Pratt, Guy</creator><creatorcontrib>Hughes, Daniel ; Yong, Kwee ; Ramasamy, Karthik ; Stern, Simon ; Boyle, Eileen ; Ashcroft, John ; Basheer, Faisal ; Rabin, Neil ; Pratt, Guy</creatorcontrib><description>Multiple myeloma is a bone marrow‐based plasma cell tumour that develops from asymptomatic pre‐cursor conditions smouldering myeloma and monoclonal gammopathy of uncertain significance and all are characterised by the presence of a monoclonal protein in the blood. Diagnosis and distinction between these conditions is based on blood tests, the bone marrow biopsy and cross sectional imaging. There are various risk stratification models that group patients with smouldering myeloma into risk groups based on risk of progression to symptomatic disease. Management is mainly observational for patients with smouldering myeloma although clinical trials for high‐risk disease may be available. Restaging is required if evidence for progression.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.19333</identifier><identifier>PMID: 38393718</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Biopsy ; Bone imaging ; Bone marrow ; Clinical trials ; Diagnosis ; Disease Progression ; Hematology ; Humans ; MGUS ; Monoclonal gammopathy ; Monoclonal Gammopathy of Undetermined Significance - diagnosis ; Monoclonal Gammopathy of Undetermined Significance - pathology ; Monoclonal Gammopathy of Undetermined Significance - therapy ; Multiple myeloma ; Multiple Myeloma - diagnosis ; Multiple Myeloma - pathology ; Multiple Myeloma - therapy ; myeloma ; myeloma therapy ; Plasma Cells - pathology ; Risk groups ; Smoldering Multiple Myeloma - diagnosis ; Smoldering Multiple Myeloma - pathology ; Smoldering Multiple Myeloma - therapy</subject><ispartof>British journal of haematology, 2024-04, Vol.204 (4), p.1193-1206</ispartof><rights>2024 British Society for Haematology and John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3883-32980f1b19ca82cc01dd6bb8946373ac4d6d77133ed9cda704135340044279fd3</citedby><cites>FETCH-LOGICAL-c3883-32980f1b19ca82cc01dd6bb8946373ac4d6d77133ed9cda704135340044279fd3</cites><orcidid>0000-0002-6937-2852 ; 0000-0002-6487-276X ; 0000-0003-3385-3707 ; 0000-0002-4998-5205</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.19333$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.19333$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38393718$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hughes, Daniel</creatorcontrib><creatorcontrib>Yong, Kwee</creatorcontrib><creatorcontrib>Ramasamy, Karthik</creatorcontrib><creatorcontrib>Stern, Simon</creatorcontrib><creatorcontrib>Boyle, Eileen</creatorcontrib><creatorcontrib>Ashcroft, John</creatorcontrib><creatorcontrib>Basheer, Faisal</creatorcontrib><creatorcontrib>Rabin, Neil</creatorcontrib><creatorcontrib>Pratt, Guy</creatorcontrib><title>Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Multiple myeloma is a bone marrow‐based plasma cell tumour that develops from asymptomatic pre‐cursor conditions smouldering myeloma and monoclonal gammopathy of uncertain significance and all are characterised by the presence of a monoclonal protein in the blood. Diagnosis and distinction between these conditions is based on blood tests, the bone marrow biopsy and cross sectional imaging. There are various risk stratification models that group patients with smouldering myeloma into risk groups based on risk of progression to symptomatic disease. Management is mainly observational for patients with smouldering myeloma although clinical trials for high‐risk disease may be available. Restaging is required if evidence for progression.</description><subject>Biopsy</subject><subject>Bone imaging</subject><subject>Bone marrow</subject><subject>Clinical trials</subject><subject>Diagnosis</subject><subject>Disease Progression</subject><subject>Hematology</subject><subject>Humans</subject><subject>MGUS</subject><subject>Monoclonal gammopathy</subject><subject>Monoclonal Gammopathy of Undetermined Significance - diagnosis</subject><subject>Monoclonal Gammopathy of Undetermined Significance - pathology</subject><subject>Monoclonal Gammopathy of Undetermined Significance - therapy</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - diagnosis</subject><subject>Multiple Myeloma - pathology</subject><subject>Multiple Myeloma - therapy</subject><subject>myeloma</subject><subject>myeloma therapy</subject><subject>Plasma Cells - pathology</subject><subject>Risk groups</subject><subject>Smoldering Multiple Myeloma - diagnosis</subject><subject>Smoldering Multiple Myeloma - pathology</subject><subject>Smoldering Multiple Myeloma - therapy</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10MFO3DAUhWGrKioD7aIvUFnqBhYB39wkdrobKDAgpCK1XVuO7QwexfFgJ6ry9gQGWCDVG28-_bo6hHwFdgLzO2029ydQI-IHsgCsyiyHAj6SBWOMZ8AKsU8OUtowBshK-ET2UWCNHMSCtD-dWvchuURVb6hXvVpbb_uBhpYmH8bO2Oj6NfWT7YJXP-iSnkU3uHRPfwft7DDRNkS6UtarIXRhPdGrEAy9i0oPTlt6p7Y2fiZ7reqS_fLyH5K_lxd_zlfZ7a-r6_PlbaZRCMwwrwVroYFaK5FrzcCYqmlEXVTIUenCVIZzQLSm1kZxVgCWWDBWFDmvW4OH5GjX3cbwMNo0SO-Stl2nehvGJPO6rCrBsOIz_f6ObsIY-_k6iQxLyMucP6njndIxpBRtK7fReRUnCUw-jS_n8eXz-LP99lIcG2_Nm3xdewanO_DPdXb6f0me3ax2yUcru4yC</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Hughes, Daniel</creator><creator>Yong, Kwee</creator><creator>Ramasamy, Karthik</creator><creator>Stern, Simon</creator><creator>Boyle, Eileen</creator><creator>Ashcroft, John</creator><creator>Basheer, Faisal</creator><creator>Rabin, Neil</creator><creator>Pratt, Guy</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6937-2852</orcidid><orcidid>https://orcid.org/0000-0002-6487-276X</orcidid><orcidid>https://orcid.org/0000-0003-3385-3707</orcidid><orcidid>https://orcid.org/0000-0002-4998-5205</orcidid></search><sort><creationdate>202404</creationdate><title>Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper</title><author>Hughes, Daniel ; Yong, Kwee ; Ramasamy, Karthik ; Stern, Simon ; Boyle, Eileen ; Ashcroft, John ; Basheer, Faisal ; Rabin, Neil ; Pratt, Guy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3883-32980f1b19ca82cc01dd6bb8946373ac4d6d77133ed9cda704135340044279fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biopsy</topic><topic>Bone imaging</topic><topic>Bone marrow</topic><topic>Clinical trials</topic><topic>Diagnosis</topic><topic>Disease Progression</topic><topic>Hematology</topic><topic>Humans</topic><topic>MGUS</topic><topic>Monoclonal gammopathy</topic><topic>Monoclonal Gammopathy of Undetermined Significance - diagnosis</topic><topic>Monoclonal Gammopathy of Undetermined Significance - pathology</topic><topic>Monoclonal Gammopathy of Undetermined Significance - therapy</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - diagnosis</topic><topic>Multiple Myeloma - pathology</topic><topic>Multiple Myeloma - therapy</topic><topic>myeloma</topic><topic>myeloma therapy</topic><topic>Plasma Cells - pathology</topic><topic>Risk groups</topic><topic>Smoldering Multiple Myeloma - diagnosis</topic><topic>Smoldering Multiple Myeloma - pathology</topic><topic>Smoldering Multiple Myeloma - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hughes, Daniel</creatorcontrib><creatorcontrib>Yong, Kwee</creatorcontrib><creatorcontrib>Ramasamy, Karthik</creatorcontrib><creatorcontrib>Stern, Simon</creatorcontrib><creatorcontrib>Boyle, Eileen</creatorcontrib><creatorcontrib>Ashcroft, John</creatorcontrib><creatorcontrib>Basheer, Faisal</creatorcontrib><creatorcontrib>Rabin, Neil</creatorcontrib><creatorcontrib>Pratt, Guy</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hughes, Daniel</au><au>Yong, Kwee</au><au>Ramasamy, Karthik</au><au>Stern, Simon</au><au>Boyle, Eileen</au><au>Ashcroft, John</au><au>Basheer, Faisal</au><au>Rabin, Neil</au><au>Pratt, Guy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2024-04</date><risdate>2024</risdate><volume>204</volume><issue>4</issue><spage>1193</spage><epage>1206</epage><pages>1193-1206</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Multiple myeloma is a bone marrow‐based plasma cell tumour that develops from asymptomatic pre‐cursor conditions smouldering myeloma and monoclonal gammopathy of uncertain significance and all are characterised by the presence of a monoclonal protein in the blood. Diagnosis and distinction between these conditions is based on blood tests, the bone marrow biopsy and cross sectional imaging. There are various risk stratification models that group patients with smouldering myeloma into risk groups based on risk of progression to symptomatic disease. Management is mainly observational for patients with smouldering myeloma although clinical trials for high‐risk disease may be available. Restaging is required if evidence for progression.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>38393718</pmid><doi>10.1111/bjh.19333</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-6937-2852</orcidid><orcidid>https://orcid.org/0000-0002-6487-276X</orcidid><orcidid>https://orcid.org/0000-0003-3385-3707</orcidid><orcidid>https://orcid.org/0000-0002-4998-5205</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2024-04, Vol.204 (4), p.1193-1206 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2956680367 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Biopsy Bone imaging Bone marrow Clinical trials Diagnosis Disease Progression Hematology Humans MGUS Monoclonal gammopathy Monoclonal Gammopathy of Undetermined Significance - diagnosis Monoclonal Gammopathy of Undetermined Significance - pathology Monoclonal Gammopathy of Undetermined Significance - therapy Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - pathology Multiple Myeloma - therapy myeloma myeloma therapy Plasma Cells - pathology Risk groups Smoldering Multiple Myeloma - diagnosis Smoldering Multiple Myeloma - pathology Smoldering Multiple Myeloma - therapy |
| title | Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A26%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnosis%20and%20management%20of%20smouldering%20myeloma:%20A%20British%20Society%20for%20Haematology%20Good%20Practice%20Paper&rft.jtitle=British%20journal%20of%20haematology&rft.au=Hughes,%20Daniel&rft.date=2024-04&rft.volume=204&rft.issue=4&rft.spage=1193&rft.epage=1206&rft.pages=1193-1206&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.19333&rft_dat=%3Cproquest_cross%3E2956680367%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3035125277&rft_id=info:pmid/38393718&rfr_iscdi=true |